When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MOR - MorphoSys up 5% premarket on tafasitamab data
MorphoSys AG
Thinly traded MorphoSys AG (NASDAQ:MOR) is up 5% premarket on light volume in reaction to data from a Phase 2 clinical trial, L-MIND, evaluating tafasitamab (MOR208), combined with Celgene's (NASDAQ:CELG) Revlimid (lenalidomide), in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) who were ineligible for high-dose chemo and autologous stem cell transplantation. The results, originally announced in May, were presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland.
More news on: MorphoSys AG, Celgene Corporation, Healthcare stocks news, Stocks on the move,